

ملاحظات:



The Effect of Intravesical OnabotulinumtoxinA (Botox) Injections on Urinary Bladder Functions in Children

Thesis

*Submitted For Partial Fulfillment of M.D. Degree in
Pediatric Surgery*

By

Abd El-Wahed Mohammad Abd EL-Wahed Mohammad
M.Sc., M.B, B.CH., Ain Shams University

Under Supervision of

Prof. Dr. Osama Abd El Elah Gaber AL Nagar

*Professor of Paediatric Surgery
Faculty of Medicine-Ain Shams University*

Prof. Dr. Amr Abd El Hamed Zaki Abu Zaid

*Professor of Paediatric Surgery
Faculty of Medicine-Ain Shams University*

Dr. Mohamed Mousa Dahab Ali

*Assistant Professor of Paediatric Surgery
Faculty of Medicine-Ain Shams University*

Dr. Ayman Moustafa Allam Mohmmmed

*Assistant Professor of Paediatric Surgery
Faculty of Medicine-Ain Shams University*

Dr. Mohamed Kotob Ahmed Tolba

*Assistant Professor of Urology
Faculty of Medicine-Ain Shams University*

*Faculty of Medicine
Ain Shams University*

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **Allah**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Osama Abd El Elah Gaber AL Nagar**, Professor of Paediatric Surgery, Faculty of Medicine-Ain Shams University for his keen guidance, kind supervision, continuous encouragement, which made completion of this work possible. His dedication to teach us and support are matchless. I really had the honor to complete this work under his supervision*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Amr Abd El Hamed Zaki Abu Zaid**, Professor of Paediatric Surgery, Faculty of Medicine-Ain Shams University for his kind care, genuine support, granting me much of his time and continuous training setting a role model in professorship.*

*I would like to thank **Dr. Mohamed Mousa Dahab Ali**, Assistant Professor of Paediatric Surgery, Faculty of Medicine-Ain Shams University, for his outstanding dedication, continuous support, and his patience in reviewing and correcting this work. He has always been there for me in every step.*

*I am deeply thankful to **Dr. Ayman Moustafa Allam Mohammed**, Assistant Professor of Paediatric Surgery, Faculty of Medicine-Ain Shams University for his great help, active participation, kind support and guidance. I greatly appreciate his efforts.*

*Also, I would like to thank **Dr. Mohamed Qotob Ahmed Tolba**, Assistant Professor of Urology, Faculty of Medicine-Ain Shams University who sincerely guided and supported me in every step in this work and in my career. His valuable ethics that will be kept in my mind forever.*

*I would like to express my heartfelt thanks to **all my family** for their support till this work was completed.*

Abd El-Wahed Mohammad

List of Contents

Title	Page No.
List of Tables.....	i
List of Figures.....	ii
List of Abbreviations	v
Introduction.....	1
Aim of the Study	4
Review of Literature	
📖 Embryology.....	5
📖 Anatomy	7
📖 Nervous System Control of Lower Urinary Tract	13
📖 Physiology of Lower Urinary Tract.....	17
📖 Pathophysiology	23
📖 Clinical Picture.....	29
📖 Diagnosis	38
📖 Treatment.....	47
Patients and Methods	76
Results	66
Discussion.....	85
Summary	108
Conclusion and Recommendations	98
References.....	99
Arabic Summary	--

List of Tables

Table No.	Title	Page No.
Table (1):	Diagnostic Criteria for Functional Constipation must include 2 or more of the following occurring at least once per week for a minimum of 1 month with insufficient criteria for a diagnosis of irritable bowel syndrome.....	33
Table (2):	Dysfunctional voiding symptom score	34
Table (3):	The mean \pm SD for DVSS and urodynamic findings before and after Botox injection.....	77
Table (4):	Mixed-design ANOVA was calculated to examine the effects of type of bladder dysfunction (non neurogenic and neurogenic) and time (pre and post injection) on dysfunctional voiding score.	77
Table (5):	Mixed-design ANOVA was calculated to examine the effects of type of bladder dysfunction (non neurogenic and neurogenic) and time (pre and post injection) on max detrusor pressure.....	78
Table (6):	Mixed-design ANOVA was calculated to examine the effects of type of bladder dysfunction (non neurogenic and neurogenic) and time (pre and post injection) on maximum cystometric capacity MCC	78
Table (7):	Lower urinary tract symptoms before and after Botox injections.....	82
Table (8):	Urodynamic values for the patients before and after Botox injections	84

List of Figures

Fig. No.	Title	Page No.
Fig (1):	Diagram of urogenital sinus, lateral view, as the bladder enlarges, distal parts of the mesonephric ducts are incorporated into its posterior wall as the trigone.....	6
Fig (2):	Lower urinary tract anatomy including bladder and urethra.	9
Fig (3):	Diagram of urethrogram and urethrogram showing landmarks of normal structures.....	11
Fig (4):	VCU showing slight narrowing (large arrow) at the junction between the posterior and the anterior urethra corresponds to the urogenital diaphragm.....	12
Fig (5):	Nervous system control of lower urinary tract	16
Fig (6):	A: Normal (bell shaped) urinary flow curves of 2 children. B: Flow curves of 2 children with a static, anatomic obstruction; the curve is continuous but the flow is lower than normal and extended in time. C: Interrupted flow curve in a child with either discoordination between bladder contraction and sphincter relaxation (pelvic floor muscles) or underactive bladder with abdominal straining to empty	21
Fig (7):	A vicious cycle in Hinman syndrome. LUTD, lower urinary tract dysfunction; LUTS, lower urinary tract symptoms; UTI, urinary tract infection	25
Fig (8):	Bladder diary over 96 h (=2 weekends).....	34
Fig (9):	Illustration showing the Bristol Stool Chart (Source: The Organic Dietitian). Source: Wikipedia Commons. Bristol Stool Scale.....	35
Fig (10):	VCUG for a 9 years old male patient with nonneurogenic neurogenic bladder. UB trabeculations and UB diverticulum (in left lateral wall) are seen.....	36
Fig (11):	Illustration showing a representation of diagnostic tools for LUTD	40

List of Figures (cont....)

Fig. No.	Title	Page No.
Fig (12):	A: VCUG showing spinning top urethra and bilateral VUR. B: VCUG showing wide bladder neck anomaly.	45
Fig (13):	VCUG film lateral view showing sacral agenesis.	46
Fig (14):	Modified vesico-cutaneous fistula in an infant with repaired meningocele and neurogenic bladder.	52
Fig (15):	Submucosal onabotulinumtoxinA (Botox) injection in trabeculated refractory idiopathic overactive bladder	58
Fig (16):	Intravesical Botox injections on 21 different points sparing trigone and ureteric orifices.	59
Fig (17):	VCUG for an 8 years old female patient with sacral agenesis (neuropathic bladder) with urge incontinence during the daytime, frequency, holding maneuvers, recurrent UTIs and fecal soiling. VCUG was showing trabeculated small (120 ml) bladder and dilated posterior urethra (neurogenic spinning top urethra).	67
Fig (18):	VCUG for a 9 years old female patient with neuropathic bladder and recurrent UTIs with urge incontinence and frequency during the daytime associated with chronic constipation and soiling. VCUG showing severely trabeculated bladder (Christmas tree appearance) (fig.17 a) significant PVR (fig.17 b), loaded colon and rectum.....	68
Fig (19):	A 13 years old male patient with repaired meningocele and neuropathic bladder and rectum. VCUG was showing trabeculated bladder and wide bladder neck sign (fig.18 a) Also rectum and colon was loaded. Noncompliance on CIC through urethra (urethral injury with frequent hematuria), modified vesico-cutaneous fistula was done (fig.18 b).....	68

List of Figures (cont....)

Fig. No.	Title	Page No.
Fig (20):	VCUG for a 10 years old male patient with recurrent UTIs with urge incontinence and frequency during the daytime and nocturnal enuresis all the days. VCUG showing small bladder 90 ml.	69
Fig (21):	VCUG for a 5 years old female patient with recurrent UTIs, urgency and frequency during the daytime (incomplete evacuation).....	69
Fig (22):	VCUG for an 8 years old female patient with urge incontinence during daytime with frequency and occasionally intermittency.....	70
Fig (23):	11 years old male patient, recurrent UTIs, urgency incontinence, fecal soiling, (nonneurogenic neurogenic bladder).	71
Fig (24):	VCUG for a 5 years old female patient with daytime urge incontinence, frequency, interrupted voiding with recurrent episodes of UTIs.....	72
Fig (25):	Column chart showing the mean DVSS before and after intravesical Botox injections.....	79
Fig (26):	Column chart showing the mean maximum detrusor pressure before and after intravesical Botox injections.....	79
Fig (27):	Column chart showing the mean maximum cystometric capacity before and after intravesical Botox injections.....	80
Fig (28):	Column chart showing mean detrusor leakage pressure before and after intravesical Botox injections.	80
Fig (29):	Column chart showing mean postvoid residue before and after intravesical Botox injections.....	81

List of Abbreviations

Abb.	Full term
AC	<i>Augmentation Cystoplasty</i>
Ach	<i>Acetyl Choline</i>
AUA	<i>American Urologic Association</i>
BBD	<i>Bladder and Bowel Dysfunction</i>
BNC	<i>Bladder Neck Closure</i>
BNR	<i>Bladder Neck Reconstruction</i>
BTX	<i>Botox</i>
CIC	<i>Clean Intermittent Catheterization</i>
CNS	<i>Central Nervous System</i>
DLP	<i>Detrusor Leak Pressures</i>
DO	<i>Detrusor Overactivity</i>
DSD	<i>Detrusor Sphincter Dyssynergia</i>
DUD	<i>Detrusor Underutilization Disorder</i>
DV	<i>Dysfunctional Voiding</i>
DV	<i>Dysfunctional Voiding</i>
DVSS	<i>Dysfunctional Voiding Symptom Score</i>
EAU	<i>European Association of Urology</i>
EDOUF	<i>Extraordinary Daytime Only Urinary Frequency</i>
EUS	<i>External Urethral Sphincter</i>
FDA	<i>US Food and Drug Administration</i>
FI	<i>Flow Index</i>
FVC	<i>Frequency / Volume Chart</i>
GI	<i>Gastrointestinal</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>IAP</i>	<i>Intraabdominal Pressure</i>
<i>ICCS</i>	<i>International Children's Continence Society</i>
<i>IDOD</i>	<i>Idiopathic Detrusor Overactivity Disorder</i>
<i>IUS</i>	<i>Internal Urethral Sphincter</i>
<i>LUT</i>	<i>Lower Urinary Tract</i>
<i>MRI</i>	<i>Magnetic Resonance Imaging</i>
<i>OAB</i>	<i>Overactive Bladder</i>
<i>PAG</i>	<i>Periaqueductal Grey</i>
<i>PBND</i>	<i>Primary Bladder Neck Dysfunction</i>
<i>PMC</i>	<i>Pontine Micturition Center</i>
<i>PTNS</i>	<i>Percutaneous Tibial Nerve Stimulation</i>
<i>PUV</i>	<i>Posterior Urethral Valve</i>
<i>PVR</i>	<i>Post Void Residual</i>
<i>SPSS</i>	<i>Statistical Package for Social Science</i>
<i>TENS</i>	<i>Transcutaneous Electrical Nerve Stimulation</i>
<i>US</i>	<i>Ultrasonography</i>
<i>VCU</i>	<i>Voiding Cystourethrography</i>
<i>VUR</i>	<i>Vesico-Ureteric Reflux</i>
<i>WBNA</i>	<i>Wide Bladder Neck Anomaly</i>
ΔV	<i>Volume Change</i>

Abstract

Background: Children with overactive bladder and urinary incontinence are probably the most difficult to manage because of the serious effects on kidney functions and social life. Botulinum toxin has shown its effectiveness in lowering the bladder pressure and obtain adequate continence with nearly no complications.

Objective: To evaluate clinical and urodynamic efficiency of intravesical OnabotulinumtoxinA (Botox) injections in children with lower urinary tract symptoms and overactive bladder. These pediatric patients were resistant to the urotherapy and the anticholinergic treatment.

Patients and Methods: Eleven patients aged from 5 to 13 years old (median age 8.5 years old), 6 males and 5 females with daytime and or nighttime urinary incontinence with lower urinary tract symptoms and detrusor overactivity detected by urodynamic study. five cases have idiopathic detrusor overactivity , four cases with neurogenic overactive bladder and two cases have detrusor sphincter dyssynergia (DSD), were treated with onabotulinumtoxinA (Botox) injections after failure of the urotherapy and anticholinergic treatment and followed up in urology clinic 3 , 6 , 9 , 12 months post injection . Assessment the patients were obtained clinically through the bladder diary and the dysfunctional voiding scoring system and by urodynamic study before and after Botox injections. We used onabotA (Botox) in 10 units / kg with maximal dose 300 units via cystoscopy into 21 different sites.

Results: We noted improvement of the urgency in all patients (totally disappeared) and frequency, in the patients with voluntary voiding who didn't require intermittent catheterization. Absence leakage during the daytime between CIC in (6 patients) and in the patient with voluntary voiding (5 patients) after Botox injections. All patients were having a daily episodes of nocturnal enuresis before Botox injections and totally disappeared in 2 patients (40%), three patients (60%) were having two episodes of nocturnal enuresis / week. after Botox injections. Remaining 6 patients, the urinary catheter was inserted during sleep. Dysfunctional voiding system score (DVSS) has been significantly decreased (marked improvement) after Botox injections, the mean was 16.73 before Botox and decreased to 6.18 after Botox (p -value < 0.001). The maximal detrusor pressure was significantly decreased in 9 patients after Botox injections, the mean was 88.67 cmH₂O before Botox and decreased to 50 cmH₂O after Botox (p-value= 0.022). The micturating cystometric capacity (MCC) was increased after Botox injections also in those 9 patients. The mean was 136.11 before Botox and was increased to 162.78 ml after Botox (p-value=0.137). The post voiding residual volume was decreased after Botox injections in 5 patients who were having voluntary voiding, the mean was 64 ml before Botox and decreased after improving the emptying function of the bladder to 24 ml after Botox injections i.e.59.6% the mean decrease in PVR after Botox injections (p-value=0.014). The detrusor leakage pressure was decreased after Botox injections in 4 patients. The mean was 80.5 cmH₂O before Botox injections and decreased to 46.5 cmH₂O after Botox injections. (P-value =0.281)

Conclusion: onabotulinumtoxinA (Botox) is an adequate alternative to more invasive surgical interventions in children with lower urinary tract symptoms and incontinence who failed medical treatment.

Keywords: onabotulinumtoxinA, children, Botox, neurogenic bladder, lower urinary tract dysfunction, incontinence.

INTRODUCTION

Children with urinary incontinence with idiopathic overactive bladder (OAB) as well as neurogenic bladder often experience inadequate storage and emptying of urine and result in serious effects on kidney functions and quality of their social lives. Prevalence of OAB varies between 15–20% and decreases with age and is reduced to levels as low as 12% in adolescent period (*Kajiwara et al., 2006*).

Overactive bladder (OAB) is a voiding dysfunction related to filling phase of the urinary bladder and defined by International Children’s Continence Society (ICCS) as “urinary urgency, usually accompanied by frequency and nocturia, with or without urinary incontinence, in the absence of urinary tract infection or any other obvious pathology (*Austin et al., 2016*).

Finding a solution for making the bladder more compliant, reduced pressure, increasing the bladder capacity, avoiding renal compromise and upper urinary tract deterioration is an essential aspect in treatment plan as well as making the ability for children to reach an improved degree of urinary continence with adequate social life through a minimally invasive approach. Nonetheless some patients respond to the usual initial treatment of overactive bladder that includes behavioral modifications, timed voiding, double voiding with clean intermittent catheterization (CIC) and approved oral medications at recommended doses (*Uçar et al., 2018*).

Children with no response to urotherapy or medical therapy or those with no tolerance to oral therapy due to side effects (dry mouth, blurred vision, constipation) are prone to the more invasive treatment methods.

Botulinum-A toxin injection was first used in urology by *Dykstra et al. in (1998)* for treatment detrusor sphincter dyssynergia (DSD) observed in patients having spinal injury. Later, application to the detrusor was described for the first time by *Schurch et al. in (2000)*. The US Food and Drug Administration (FDA) approved Botox (BTX) in 2011 for neurogenic and idiopathic detrusor overactivity and both the American Urologic Association (AUA) and the European Association of Urology (EAU) guidelines recommended intravesical onabotulinumtoxinA (Botox) injections for the patients with urgency urinary incontinence refractory to anticholinergic therapy (*Gormley et al., 2015*).

OnabotulinumtoxinA is a two-chain polypeptide neurotoxin protein produced by the bacteria *Clostridium botulinum*. The onabotulinumtoxinA is one of the seven serotype neurotoxins and inhibits acetylcholine and adenosine triphosphate release from parasympathetic presynaptic nerve terminals and causes flaccid muscle paralysis. Disruptions in the autonomic nervous system are also common where symptoms such as dry mouth, postural hypotension, and constipation can occur (*Uçar et al., 2018*).

In present study, the experience concerning the use of onabotulinumtoxinA (Botox) in children with urinary incontinence and overactive bladder to delay or avoid the need for augmentation cystoplasty, the more invasive and permanent procedure among the invasive surgical therapies, is reported. Additionally, the transient nature of onabotulinumtoxinA has allowed the option of discontinuation if results are not satisfactory or an alternative treatment is more suitable.